HPV in the Young Population: New Perspectives in Clinical Practice from Vaccination to Screening

A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Human Papillomavirus Vaccines".

Deadline for manuscript submissions: 15 August 2024 | Viewed by 1073

Special Issue Editors


E-Mail
Guest Editor
1. Department of Clinical, Surgical, Diagnostic and Paediatric Sciences, University of Pavia, 27100 Pavia, Italy
2. Department of Obstetrics and Gynecology, Fondazione IRCCS Policlinico San Matteo, 27100 Pavia, Italy
Interests: HPV; lower genital tract disease; vaccination
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Policlinico Umberto, "Sapienza" University of Study of Rome, 00100 Rome, Italy
Interests: HPV; lower genital tract disease; vaccination

E-Mail Website
Guest Editor
1. Department of Clinical, Surgical, Diagnostic and Paediatric Sciences, University of Pavia, 27100 Pavia, Italy
2. Department of Obstetrics and Gynecology, Fondazione IRCCS Policlinico San Matteo, 27100 Pavia, Italy
Interests: HPV; lower genital tract disease; vaccination
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

The introduction of HPV vaccination can prevent the development of HPV-related diseases of the genital tract. Ideally, young people should receive the vaccine before becoming sexually active. Those who are already sexually active may still benefit from immunization, since few young people are infected by all HPV strains. It is important to understand the natural history of HPV infection in order to understand the impact of infection on this population. This understanding can help promote vaccination and adherence to screening programs.

This Special Issue covers all topics related to HPV in clinical practice from vaccination to screening, and focuses on studies examining the significance of vaccines/therapeutic vaccines in the management of disease. Manuscripts of different types, including long comprehensive research articles or reviews, will be considered for publication in this Special Issue. All submissions will undergo rigorous peer review.

Dr. Mattia Dominoni
Dr. Lucia Merlino
Dr. Barbara Gardella
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • HPV
  • younger people
  • vaccination
  • cervical intraepithelial neoplasia (CIN)
  • experimental HPV vaccines
  • therapeutic HPV vaccines

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

12 pages, 3085 KiB  
Article
Using a Dynamic Model to Estimate the Cost-Effectiveness of HPV Vaccination in Iran
by Arnold Hagens, Albertus Constantijn Sloof and Roksana Janghorban
Vaccines 2024, 12(4), 438; https://doi.org/10.3390/vaccines12040438 - 18 Apr 2024
Viewed by 801
Abstract
This study aimed to determine the cost-effectiveness of vaccination against HPV. An age–sex structured dynamic disease transmission model was created to estimate the spread of HPV and the HPV-related incidence of cervical cancer (CC) in Iran. Sixteen age groups of men and women [...] Read more.
This study aimed to determine the cost-effectiveness of vaccination against HPV. An age–sex structured dynamic disease transmission model was created to estimate the spread of HPV and the HPV-related incidence of cervical cancer (CC) in Iran. Sixteen age groups of men and women were incorporated to reflect the differences in sexual preferences, vaccination uptake, and disease-related outcomes. Three scenarios were evaluated by using an Incremental Cost-Effectiveness Ratio (ICER) with gained quality-adjusted life years (QALYs). ICER values below one gross domestic product (GDP) per capita are evaluated as highly cost-effective. Vaccination reduces the number of infections and CC-related mortality. Over time, the vaccinated group ages and older age groups experience protection. An initial investment is required and savings in treatment spending reduce the impact over time. Vaccinating girls only was found to be cost-effective, with an ICER close to once the GDP per capita. Vaccinating both sexes was shown to be less cost-effective compared to girls only, and vaccinating boys only was not found to be cost-effective, with an ICER between once and three times, and greater than three times the GDP per capita, respectively. The estimates are conservative since societal cost-saving and the impact of other HPV-related illnesses were not considered and would likely reduce the ICERs. Full article
Show Figures

Figure 1

Back to TopTop